Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Beveren – page 143

2 154 clinical trials in Beveren, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Beveren at a glance
2 154
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 154 trials in Beveren

Open in trial search

Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Thyroid cancer+18

Not recruiting

Study of JK08, Pembrolizumab, and Lenvatinib for Patients with Advanced or Metastatic Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Salubris Biotherapeutics Inc.

Study to Determine the Best Dose of Vesleteplirsen for Patients with Duchenne Muscular Dystrophy Suitable for Exon 51-Skipping Treatment

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Vesleteplirsen
  • Sponsor:Sarepta Therapeutics Inc.

Epilepsy

Not recruiting

Study on the Effectiveness and Safety of Perampanel for Children with Epilepsy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Perampanel
  • Sponsor:Eisai Limited

Study of Relatlimab and Nivolumab with Chemotherapy for Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on Mavacamten for Adults with Non-obstructive Hypertrophic Cardiomyopathy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten
  • Sponsor:Myokardia Inc.

Myelofibrosis

Not recruiting

Study Comparing Fedratinib with Drug Combination for Myelofibrosis in Patients Previously Treated with Ruxolitinib

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Celgene Corp.

Diabetic nephropathy

Not recruiting

Study on the Effectiveness and Safety of Finerenone and Empagliflozin in Adults with Chronic Kidney Disease and Type 2 Diabetes

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Bayer AG

Gastric cancer+1

Not recruiting

Study on the Safety and Activity of S095029 and Pembrolizumab for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Sepsis+1

Not recruiting

Study on the Safety and Effectiveness of TIN816 for Patients with Sepsis-Related Acute Kidney Injury

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:TIN816
  • Sponsor:Novartis Pharma AG

Cardiac amyloidosis+1

Not recruiting

Study on the Effectiveness and Safety of CAEL-101 with Drug Combination for Patients with Advanced AL Amyloidosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anselamimab
  • Sponsor:Alexion Pharmaceuticals Inc.

Chronic hepatitis B+1

Not recruiting

Study on Safety and Efficacy of Bepirovirsen and Drug Combination for Chronic Hepatitis B in Patients on Nucleos(t)ide Analogue Therapy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Bepirovirsen
  • Sponsor:GlaxoSmithKline Biologicals

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Beveren

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) deprescribing strategies for patients with chronic usage patterns. The study explores alternative treatment approaches for managing functional dyspepsia and related conditions.

  • PPI Usage Optimization
  • Gastrointestinal Health
  • Medication Management

This primary care research evaluates the effectiveness of on-demand PPI use and alginate formulation as alternative treatment strategies compared to traditional tapering methods.

02 Digestive Health Studies

Clinical investigations addressing chronic heartburn and reflux management through comparative analysis of different treatment protocols. The research aims to establish optimal deprescribing approaches for long-term medication users.

  • Treatment Optimization
  • Patient-Centered Care
  • Medication Reduction Strategies

The study explores innovative approaches to reduce medication dependency while maintaining effective symptom control for patients with digestive conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.